

Issuer Information and Disclosure Statement

Manzo Pharmaceuticals, Inc.

A Wyoming Corporation

(Formerly Fortune Oil & Gas, Inc. until 9-2014,
formerly The Beverage Store Inc. until 5-1998)

385 Whitcomb Blvd

Tarpon Springs, Florida 34689

Phone (727) 202-9887, Fax (727) 807-8995

Federal EIN:

SIC Code: 6770 - Blank Checks

AUGUST 31, 2016 UPDATE REPORT

Completion of Acquisition or Disposition of Assets

Changes in Control of Issuer

Departure of Directors or Principal Officers

Election of Directors

Appointment of Principal Officers

Manzo Pharmaceuticals, Inc. is responsible for the content of this Report. The securities described in this document are not registered with, and the information contained in this report has not been filed with, or approved by, the U.S. Securities and Exchange Commission.

TABLE OF CONTENTS

Item 1	Completion of Acquisition or Disposition of Assets	3
Item 2	Changes in Control of Issuer	3
Item 3	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	3
Item 4	Issuer's Certifications	4

UPDATED AUGUST 31, 2016 REPORT

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this updated August 31, 2016 Report (the “Report”) contains forward-looking statements, which involve a number of risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements can be identified by the use of the words “expect,” “project,” “may,” “might,” “potential,” and similar terms. Manzo Pharmaceuticals, Inc. (“Manzo Pharmaceuticals,” “we,” the “Issuer” or the “Issuer ”) cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements involve a number of risks, uncertainties or other factors beyond our control. These factors include, but are not limited to, our ability to implement our strategic initiatives, economic, political and market conditions and price fluctuations, government and industry regulation, U.S. and global competition, and other factors. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

**IT IS IMPORTANT TO NOTE THAT ANY INVESTMENT
IN THE ISSUER WOULD INVOLVE A VERY HIGH RISK.**

Item 1: Completion of Disposition of Assets

On August 22, 2016, it was announced that Manzo Pharmaceuticals CEO Kenneth Manzo Milford, the Issuer's Chief Executive Officer resigned in connection with a settlement with the U.S. Securities and Exchange Commission (SEC). The SEC settlement bars Mr. Manzo from being an officer or director of the Issuer.

The Issuer was dependent upon the personal financial support of Mr. Manzo, who had never taken any salary. The Issuer cannot develop its business plan without the services and funding of Mr. Manzo. Therefore, the Issuer has conveyed Manzo Pharmaceuticals, LLC back to Mr. Manzo in exchange for all of Mr. Manzo's common stock in the Issuer, two hundred million shares. This transfer leaves the Issuer without operations or a material amount of assets.

At present, the Issuer intends to start to study ways to increase shareholder value. **There is no assurance that the Issuer will be successful in this endeavor.**

Item 2: Changes in Control of Issuer

In connection with Mr. Manzo's departure from the Issuer, Mr. Manzo sold his Preferred stock in the Issuer. The 4,000,000 shares of Series A Preferred Stock formerly owned by Mr. Manzo is now owned by Gerasimos Alexander Antonios Morfesis.

Item 3: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

The Issuer has accepted Mr. Manzo's resignation as an officer and director of the Issuer. The 4,000,000 shares of Manzo Pharmaceuticals, Inc. Series A Preferred Stock have been conveyed to Gerasimos Alexander Antonios Morfesis.

Mr. Morfesis' address is 385 Whitcomb Boulevard, Tarpon Springs, Florida 34689. Mr. Morfesis is a real estate investor.

Arthur Smitherman, who had been the only remaining director of the Issuer, has been

removed and Mr. Morfesis is now the sole director of the Issuer.

Mr. Morfesis is a real estate investor with previous holdings in Chicago and the Tampa Bay area of Florida.

Mr. Morfesis was Involved in the “Black Metropolis” redevelopment plan in Chicago, and worked on the local board of a Habitat for Humanity Chapter in Chicago. Mr. Morfesis helped restructure Congress Theater in Chicago into a live venue success.

Mr. Morfesis has worked for a number of years in legal support work, researching and developing esoteric and successful defenses against bank attempts to improperly convert homeowners equity in the judicial foreclosure process. He has experience in restructurings and renegotiations of debts.

Mr. Morfesis attended Fairleigh Dickinson University and City College of New York. He has previously held a Mortgage License in Florida and real estate licenses in New York and Illinois.

Mr. Morfesis has no disciplinary history whatsoever, and has never had a criminal conviction, entry of a judgment or decree by a court of any jurisdiction that limited his involvement with any type of business, securities, commodities, or banking activities. Furthermore they have never had a finding or judgment against them nor any order by self-regulatory organizations of any kind.

As of the date of this information statement the only individual or entity owning more than 10% of the company’s common or preferred securities is as follows:

Gerasimos Alexander Antonios Morfesis
385 Whitcomb Boulevard
Tarpon Springs, Florida 34689

Ownership: 4,000,000 Shares of Preferred Series A Shares

Item 4: Issuer's Certifications

The Issuer shall include certifications by the chief executive officer and chief financial officer of the Issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Gerasimos Alexander Antonios Morfesis, President of Manzo Pharmaceuticals, Inc. , certify that:

1. I have reviewed this quarterly disclosure statement of Manzo Pharmaceuticals, Inc. ;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the Issuer as of, and for, the periods presented in this disclosure statement.

Date: September 6, 2016



Gerasimos Alexander Antonios Morfesis
President